|
Model Number HERO 1001 |
Device Problems
Adverse Event Without Identified Device or Use Problem (2993); Insufficient Information (3190)
|
Patient Problems
Arthritis (1723); Bacterial Infection (1735); Unspecified Infection (1930); Sepsis (2067); Synovitis (2094); Injury (2348); Test Result (2695)
|
Event Type
Injury
|
Manufacturer Narrative
|
This investigation is currently ongoing.Any additional information will be provided in the follow-up report.
|
|
Event Description
|
According to the publication, "prospective analysis of hemodialysis reliable outflow vascular access graft vs.Cuffed catheter access in hemodialysis," the prospective cohort study assessed clinical outcomes in 16 hero graft patients against a control group without hero (n=17) over one year.The adverse events associated with each patient are being reported collectively per patient as a determination could not be made regarding the relation of the associated events.Furthermore, the specific patient comorbidities and contributory factors for the reported adverse events cannot be correlated.The most common etiology of end-stage renal disease (esrd) was diabetes, hypertension, or the combination of both.The most common comorbidities in both study groups were diabetes mellitus, hypertension, and myocardial infarction.This medwatch is being submitted as product code hero 1001, however the scope of the investigation will evaluate both hero 1001 and hero 1002 components.This report is being submitted for patient 019.Patient 019 was a male who received a hero implant on (b)(6) 2012 was hospitalized on (b)(6) 2012 for "infection septic arthritis, gram positive cocci resembling strep group b" with presumed source "right hand tenosynovitis." the patient was also hospitalized on (b)(6) 2012 for "fall, leg and face injury.".
|
|
Manufacturer Narrative
|
According to the publication, "prospective analysis of hemodialysis reliable outflow vascular access graft vs.Cuffed catheter access in hemodialysis," the prospective cohort study assessed clinical outcomes in 16 hero graft patients against a control group without hero (n=17) over one year.The adverse events associated with each patient are being reported collectively per patient as a determination could not be made regarding the relation of the associated events.Furthermore, the specific patient comorbidities and contributory factors for the reported adverse events cannot be correlated.The most common etiology of end-stage renal disease (esrd) was diabetes, hypertension, or the combination of both.The most common comorbidities in both study groups were diabetes mellitus, hypertension, and myocardial infarction.This medwatch is being submitted as product code hero 1001, however the scope of the investigation will evaluate both hero 1001 and hero 1002 components.This report is being submitted for patient (b)(6).Patient (b)(6) was a male who received a hero implant on (b)(6) 2012 was hospitalized on (b)(6) 2012 for "infection septic arthritis, gram positive cocci resembling strep group b" with presumed source "right hand tenosynovitis." the patient was also hospitalized on (b)(6) 2012 for "fall, leg and face injury." the manufacturing records for lots 0001530 and 0001531 were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.Patient (b)(6) had a hero graft implanted on (b)(6) 2012.The patient was hospitalized twice in (b)(6) 2012.In early (b)(6), the patient was hospitalized for "fall, leg and face injury." this incident was unrelated to hero graft implant.In (b)(6), the patient was hospitalized for "infection septic arthritis, gram positive cocci resembling strep group b" with presumed source "right hand tenosynovitis." this incident was also unrelated to hero graft implant.Based on the information provided, there is no relationship between the hero graft and both hospitalizations.
|
|
Event Description
|
According to the publication, "prospective analysis of hemodialysis reliable outflow vascular access graft vs.Cuffed catheter access in hemodialysis," the prospective cohort study assessed clinical outcomes in 16 hero graft patients against a control group without hero (n=17) over one year.The adverse events associated with each patient are being reported collectively per patient as a determination could not be made regarding the relation of the associated events.Furthermore, the specific patient comorbidities and contributory factors for the reported adverse events cannot be correlated.The most common etiology of end-stage renal disease (esrd) was diabetes, hypertension, or the combination of both.The most common comorbidities in both study groups were diabetes mellitus, hypertension, and myocardial infarction.This medwatch is being submitted as product code hero 1001, however the scope of the investigation will evaluate both hero 1001 and hero 1002 components.This report is being submitted for patient (b)(6).Patient (b)(6) was a male who received a hero implant on (b)(6) 2012 was hospitalized on (b)(6) 2012 for "infection septic arthritis, gram positive cocci resembling strep group b" with presumed source "right hand tenosynovitis." the patient was also hospitalized on (b)(6) 2012 for "fall, leg and face injury.".
|
|
Search Alerts/Recalls
|
|
|